| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dab7fd26f3cb605aab550ed208a2fe8c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 |
| filingDate |
2022-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d5f0e61c320945c233de1e2dcb701dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1f04f42456495432b892eff939dfc4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82ba42fcbe7b29c83ee88cda28629ee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c9c7009d2f42504fb0b137847368ed7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d252b1948dded728ea48b5c2c559f0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1f442b293538ebcb950ec6ca51bbf42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe66874755fa868b1c9c0e795cf891c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_738985ea478ed1abf61db87b4bdb1df1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d113fd49240a51eeccaf9e622093f06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5bbacee049c296695f2ca04c0acbe8f |
| publicationDate |
2022-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022232504-A1 |
| titleOfInvention |
19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| abstract |
The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11780875-B2 |
| priorityDate |
2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |